Mereo BioPharma Group plc American Depositary Shares (MREO)

Price$0.31

Value ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-91.18%

Price vs S&P 500 (4W)25.49%

VGM Score50.57

Market Capitalization$50.76M

All Metrics

Book Value / Share (Quarterly)$0.04

P/TBV (Annual)9.00x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$0.01

Price vs S&P 500 (YTD)-33.00%

EPS (TTM)$-0.05

10-Day Avg Trading Volume11.78M

EPS Excl Extra (TTM)$-0.05

EPS (Annual)$-0.05

ROI (Annual)-65.04%

Gross Margin (Annual)73.40%

Cash / Share (Quarterly)$0.05

ROA (Last FY)-56.62%

EBITD / Share (TTM)$-0.05

ROE (5Y Avg)-50.82%

Cash Flow / Share (Annual)$-0.04

P/B Ratio1.49x

P/B Ratio (Quarterly)1.55x

Net Income / Employee (Annual)$-1,073,800

Net Interest Coverage (TTM)-8.46x

ROA (TTM)-72.88%

EV / EBITDA (TTM)0.08x

EPS Incl Extra (Annual)$-0.05

Current Ratio (Annual)5.40x

Quick Ratio (Quarterly)6.32x

3-Month Avg Trading Volume3.25M

52-Week Price Return-87.27%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.04

P/S Ratio (Annual)101.52x

Asset Turnover (Annual)0.15x

52-Week High$3.05

EPS Excl Extra (Annual)$-0.05

CapEx CAGR (5Y)91.99%

26-Week Price Return-83.25%

Quick Ratio (Annual)5.38x

13-Week Price Return-19.90%

Total Debt / Equity (Annual)0.09x

Current Ratio (Quarterly)6.48x

Enterprise Value$14.53M

Revenue / Employee (Annual)$12,800

Pretax Margin (Annual)-8375.60%

Cash / Share (Annual)$0.09

3-Month Return Std Dev86.10%

Net Income / Employee (TTM)$-1,076,700

ROE (Last FY)-70.94%

Net Interest Coverage (Annual)-1.79x

EPS Basic Excl Extra (Annual)$-0.05

EV / Free Cash Flow (TTM)3.60x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.05

ROI (TTM)-83.24%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.08

Price vs S&P 500 (52W)-111.63%

Year-to-Date Return-24.84%

5-Day Price Return1.75%

EPS Normalized (Annual)$-0.05

ROA (5Y Avg)-74.73%

Net Profit Margin (Annual)-8375.60%

Month-to-Date Return-8.95%

Cash Flow / Share (TTM)$-4.46

EBITD / Share (Annual)$-0.06

Operating Margin (Annual)-8021.40%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)12.64x

ROI (5Y Avg)-39.82%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.05

P/TBV (Quarterly)1.56x

P/B Ratio (Annual)8.91x

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-28.15%

Beta0.31x

Revenue / Share (TTM)$0.00

ROE (TTM)-83.24%

52-Week Low$0.20

vGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.01est. -0.01

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

4.07

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
MREOMereo BioPharma Group plc American Depositary Shares	B	—	D	$0.31
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Mereo BioPharma is a UK-based biopharmaceutical company developing treatments for rare genetic disorders. Its lead candidates are setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-related lung disease, both in late-stage clinical development.